Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Remotely-supervised transcranial direct current stimulation (tDCS) for clinical trials: guidelines for technology and protocols.
Genetic proof for the transient nature of the Th17 phenotype.
Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.
Efferent manifestations of multiple sclerosis.
Sleep abnormality in neuromyelitis optica spectrum disorder.
Nutraceuticals against Neurodegeneration: A Mechanistic Insight.
Physical fitness, walking performance, and gait in multiple sclerosis.
Coping Among Individuals With Multiple Sclerosis: Evaluating a Goodness-of-Fit Model.
Multiple sclerosis: Pegylated IFN-β1a could lessen patients' injection burden.
Employment among Patients with Multiple Sclerosis-A Population Study.
Postural control strategy during standing is altered in patients with multiple sclerosis.
Multiple sclerosis drugs: how much bang for the buck?
Aquaporin-4 mediates communication between astrocyte and microglia: Implications of neuroinflammation in experimental Parkinson's disease.
Drugs that Treat Skin Conditions May Help Combat Multiple Sclerosis.
Study of curcumin immunomodulatory effects on reactive astrocyte cell function.
Quantification of diagnostic biomarkers to detect multiple sclerosis lesions employing (1)H-MRSI at 3T.
An initial validation of the Italian Mishel Uncertainty Illness Scale (MUIS) for relapsing remitting multiple sclerosis patients.
Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
Dietary habits and selenium, glutathione peroxidase and total antioxidant status in the serum of patients with relapsing-remitting multiple sclerosis.
Should optical coherence tomography be used to manage patients with multiple sclerosis?
Molecular biomarkers of neurodegeneration.
Levetiracetam for neuropathic pain in adults.
Very Frequent Fallers and Future Fall Injury: Continuous Risk Among Community-Dwelling Home Care Recipients.
Targeting intrinsically disordered proteins in rational drug discovery.
PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study.

Pages